Athira Pharma Inc reports results for the quarter ended in December - Earnings Summary

LeonaBio

23/03/2023 21:01

* Athira Pharma Inc  ATHA.OQ  reported a quarterly adjusted
loss
of 53 cents​​ per share for the quarter ended in December. The
mean expectation of five analysts for the quarter was for a loss
of 67 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Athira Pharma Inc's reported EPS for the quarter was a
loss
of 79 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Athira Pharma Inc shares had fallen by 21.5% this quarter.
    * The company reported a quarterly loss of $30.14 million.
    * Wall Street's median 12-month price target for Athira
Pharma Inc
is $5.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 23 at 09:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.67          -0.53          Beat
 Sep. 30 2022      -0.63          -0.53          Beat
 Jun. 30 2022      -0.64          -0.65          Missed
 Mar. 31 2022      -0.55          -0.56          Missed